Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-10-10
2009-02-03
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S009100
Reexamination Certificate
active
07485299
ABSTRACT:
Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
REFERENCES:
patent: 6048970 (2000-04-01), Lal et al.
patent: 6329503 (2001-12-01), Afar et al.
patent: 6833438 (2004-12-01), Afar et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0146692 (2002-10-01), Yamazaki et al.
patent: 2002/0192763 (2002-12-01), Xu et al.
patent: 2003/0045682 (2003-03-01), Afar
patent: 2003/0060612 (2003-03-01), Goddard et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: 2003/0100540 (2003-05-01), Zhang et al.
patent: 0834563 (1998-04-01), None
patent: WO 94/09150 (1994-04-01), None
patent: WO 98/18489 (1998-05-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/53071 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/61469 (1999-02-01), None
patent: WO 99/62941 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/35937 (2000-06-01), None
patent: WO 00/77021 (2000-12-01), None
patent: WO 01/12662 (2001-02-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/40276 (2001-06-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/57190 (2001-08-01), None
patent: WO 01/57273 (2001-08-01), None
patent: WO 01/57276 (2001-08-01), None
patent: WO 01/57277 (2001-08-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 01/72962 (2001-10-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/86003 (2001-11-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/26822 (2002-04-01), None
patent: WO 02/30268 (2002-04-01), None
patent: WO 02/077013 (2002-10-01), None
patent: WO 02/077186 (2002-10-01), None
patent: WO 02/089747 (2002-11-01), None
patent: WO 02/092787 (2002-11-01), None
patent: WO 03/004623 (2003-01-01), None
patent: WO 03/009814 (2003-02-01), None
patent: WO 03/022995 (2003-03-01), None
patent: WO 2005/113601 (2005-12-01), None
patent: WO 03/022995 (2006-03-01), None
patent: WO 2006/034488 (2006-03-01), None
Porkka et al., Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate, Lab. Invest. Nov. 2002;82(11):1573-82.
Korkmaz et al., Molecular cloning and characterization of STAMP1, a highly prostate specific six-trans-membrane protein that is overexpressed in prostate, J. Biol. Chem. 277:36689-36696(2002).
Fu et al., EMBO Journal 15:4392-4401 (1996).
Greenberg et al., PNAS 92:3439 (1995).
Grimes et al., “Electrophysiological characterization of voltage-gated NA+current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer,” Journal of Cellular Physiology 175:50-58 (1998).
Gura, Science 278:1041-1042 (1997).
Gutierrrez et al., “Activation of a Ca2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line,” Journal of Physiology 517:95-107 (1999).
Haverstick et al., “Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+entry,” Cancer Research pp. 1002-1008 (2000).
Hubert et al., PNAS USA 96(25):14523-14528 (1999).
Hunt et al., Science 255:1261-1263 (1992).
Lazar et al., Mol Cell. Biol. 8(3):1247-1252 (1988).
Lepple-Weinhues et al., “K+ channels and the intracellular calcium signal in human melanoma cell proliferation,” J. Membrane Biol. 151:149-157 (1996).
Lewin, Genes VI, Oxford University Press, Inc. NY, Chapter 29, 1997.
Marino et al., “Association between cell membrane potential and breast cancer,” Tumor Biol. 15:82-89 (1994).
McClean et al., Eur. J. of Cancer 29A:2243-2248 (1993).
Muller et al., Mol. Cell. Biol. 11:1785 (1991).
Nie et al., “Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel,” Celll Calcium 22(2):75-82 (1997).
Pancrazio et al., “Voltage-dependent ion channels in small-cell lung cancer cells,” Cancer Research 49:5901-5906 (1989).
Parker et al., J. Immunol. 152:163-175 (1994).
Peshwa et al., Prostate 36:129-138 (1998).
Rama et al., Biochem J. 318:333-341 (1996).
Shantz et al., Int. J. Biochem. Cell Bio. 31:107-122 (1999).
Skryma et al., “Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation,” The Prostate 33:112-122 (1997).
Spitler, Cancer Biotherapy 10:1-3 (1995).
Stewart et al., Genome Res. &:422 (1997).
Walter et al., Nat. Genetics 7:22 (1994).
Xue et al., Prostate 30:73-78 (1997).
Zimmer, Cell Motility and the Cytoskeleton 20:325-337 (1991).
Alberts et al., Molecular Biology of the Cell, 3rdedition (1994) p. 465.
Bellone et al., Immunolgoy Today (1999) 20(10):457-462.
Bowie et al, Science 247:1306-1310 (1990).
Brennan et al., Journal of Autoimmunity 2(suppl.): 177-186 (1989).
Burgess et al., J. Cell Biol. 111:2129-2138 (1990).
Database EMBL Nucleotide and Protein Sequences, Aug. 25, 1996, XP002128081, AA032221, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, Jun. 15, 1998, XP002128084, AC004969 (clone DJ112E10), Hinxton, GB.
Database EMBL, “Human BAC Clone CTB-167B5 form 7q21, complete sequence,”, Jun. 17, 1998, XP002173859, AC003991, R. Waterston et al.
Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB.
Diss et al., “Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines,” FEBS Letters 427:5-10 (1998).
Eriksson et al., Diabetologia 35:143-147 (1992).
Falk et al., Nature 351:390-296 (1991).
Challita-Eid Pia M., et al., “Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo”, vol. 67, No. 12, pp. 5798-5805, (2007).
Faris M., et al., “Validation of STEAP-1 as a cell surface cancer therapeutic target”, Proceedings of the annual meeting of the American Association for Cancer Research, vol. 43, p. 947, (2002).
Afar Daniel E.
Hubert Rene S.
Mitchell Stephen Chappell
Raitano Arthur B.
Saffran Douglas C.
Agarwal Atulya
Agensys, Inc.
Dreger, Esq. Ginger R.
Marschang Diane
Yu Misook
LandOfFree
Serpentine transmembrane antigens expressed in human cancers... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serpentine transmembrane antigens expressed in human cancers..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serpentine transmembrane antigens expressed in human cancers... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4057313